BIGBEAR
PHARMACEUTICAL
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy Enasidenib is an oral targeted therapy used for acute myeloid leukemia (AML) that exerts its effects by blocking isocitrate dehydrogenase-2 (IDH2).Mec···【More】
Update: 09 May,2026Source: BigbearViews: 109
Enasidenib is an oral medication used to treat acute myeloid leukemia (AML) in adult patients. Acute myeloid leukemia (AML) is a type of cancer that a···【More】
Update: 09 May,2026Source: BigbearViews: 128
August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【More】
Update: 08 May,2026Source: BigbearViews: 126
On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【More】
Update: 08 May,2026Source: BigbearViews: 115
Enasidenib dosage and administration must strictly follow the doctor's instructions and be administered under the guidance of a professional physi···【More】
Update: 24 Mar,2026Source: BigbearViews: 121
Enasidenib is the first FDA-approved treatment for acute myeloid leukemia (AML) targeting IDH2 mutations, indicated for relapsed or refractory adult p···【More】
Update: 18 Mar,2026Source: BigbearViews: 127
Precautions for EnxidipineEnxidipine is used for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. An FDA-approved diagnostic···【More】
Update: 18 Mar,2026Source: BigbearViews: 122
August 1, 2017 – The U.S. Food and Drug Administration (FDA) approved enasidenib for the treatment of adult patients with relapsed or refractory acute···【More】
Update: 10 Mar,2026Source: BigbearViews: 133
In addition to the expected therapeutic effects, some adverse reactions may occur when receiving enasidenib treatment. While not all side effects will···【More】
Update: 10 Mar,2026Source: BigbearViews: 121
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 10 Mar,2026Source: BigbearViews: 117
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 09 Mar,2026Source: BigbearViews: 118
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【More】
Update: 09 Mar,2026Source: BigbearViews: 118
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【More】
Update: 09 Mar,2026Source: BigbearViews: 115
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
